bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a le...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...
-DoseMe, a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Au...
FibroBiologics, , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...
Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in pat...
Invisalign® Palatal Expanders offer doctors an effective and easily removable alternative to traditional palatal expanders, without the need for meta...
Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic agreement to partner with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaf...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...
ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around t...
First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial, CLARIFY. The aim of the CLARIFY trial is to detect regional nodal...
© 2025 Biopharma Boardroom. All Rights Reserved.
